8-K: Glaukos Corporation Unveils Investor Presentation, Highlights Innovation and Growth Strategy

Glaukos Corporation's investor presentation emphasizes its commitment to innovation and addressing unmet needs in chronic eye diseases through novel platforms and therapeutic areas.

Summary

• Glaukos Corporation presented an investor presentation in January 2025 outlining its core growth strategy.
• The company focuses on leading-edge innovation, dropless therapies, and commercial excellence.
• Glaukos has invested over $700 million in R&D since 2018 and has 14 disclosed pipeline programs in 2025, compared to 4 in 2015.
• Key commercial catalysts for 2025-2026 are centered on establishing robust growth engines with proven therapies.
• The company is focused on Interventional Glaucoma (IG) with iDose TR as a key innovation, designed to provide continuous drug therapy.
• Glaukos aims to increase IG awareness and adoption through expanded surgeon training, market access, and clinical evidence.
• The company is also advancing its rare disease program with Epioxa for keratoconus, targeting FDA approval by the end of 2025.
• Glaukos is developing iLution for demodex blepharitis and Retina XR for retinal diseases like AMD, DME, and RVO.
• The company's net sales guidance for 2024 is $377-379 million.
• Glaukos has a global infrastructure with direct operations in 17 countries and over 300 commercial personnel.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Glaukos, highlighting its innovation, pipeline progress, and financial performance. The focus on addressing unmet needs and disrupting treatment paradigms suggests a strong potential for future growth.

Positives

• Strong focus on innovation and addressing unmet needs in chronic eye diseases.
• Robust pipeline with multiple novel platforms and therapeutic areas.
• Positive clinical data for iDose TR, showing high rates of medication-free IOP control.
• Advancement of Epioxa for keratoconus with NDA submission and targeted approval.
• Solid financial performance with growing net sales and healthy gross margins.
• Global infrastructure and commercial presence in multiple countries.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the ability to successfully commercialize iDose TR, dependence on third-party suppliers, and potential disruptions at the primary facility.
• Other risks include securing reimbursement for products, compliance with regulations, and the uncertainty of clinical trial outcomes.
• Cybersecurity threats, intellectual property protection, and the ability to service indebtedness are also potential risks.

Future Outlook

Glaukos aims to continue advancing its pipeline and expanding its market presence in interventional glaucoma, rare diseases, and anterior/posterior segment pharmaceuticals, with multiple growth drivers expected to contribute to sustained adoption of IG therapies over the next decade.

Industry Context

Glaukos is positioning itself as a leader in dropless therapies and sustained-release drug delivery, aiming to disrupt traditional treatment paradigms in ophthalmology. The company's focus on interventional glaucoma and rare diseases aligns with the growing demand for innovative solutions in these areas.

Comparison to Industry Standards

• Glaukos's iDose TR competes with traditional topical medications and SLT (Selective Laser Trabeculoplasty) as a first-line therapy for glaucoma, aiming to improve patient compliance and reduce the burden of eye drops.
• The company's focus on sustained-release drug delivery aligns with industry trends towards longer-duration therapies, similar to Allergan's Durysta, but with a different mechanism and duration.
• In the keratoconus market, Glaukos's Photrexa is the first and only FDA-approved corneal cross-linking therapy, setting a high standard for efficacy and safety.
• The development of Epioxa aims to improve upon existing epi-off procedures by reducing treatment time and improving patient comfort, potentially competing with other epi-on cross-linking technologies.

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline advancements and market expansion.
• Patients: Access to innovative therapies and improved treatment options for chronic eye diseases.
• Physicians: New tools and technologies to better manage and treat their patients.
• Employees: Opportunities for growth and development within a growing company.

Next Steps

• Advance enrollment in PMA pivotal trial for iStent infinite.
• Secure EU regulatory approval for PRESERFLO MicroShunt.
• Commence US IDE trial for PRESERFLO MicroShunt.
• Conduct Phase 4 studies for iDose TR.
• Advance Phase 2b/3 clinical program for iDose TREX.
• Commence Phase 2 trial for iLution Blepharitis by end of 2025.
• Obtain FDA approval for Epioxa by end of 2025.
• Advance Phase 2 clinical program for iLink 3rd Generation.
• Advance enrollment in Phase 2 trial for IVT Multi-Kinase Inhibitor (GLK-401).

Key Dates